⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MBRX News
Moleculin Biotech, Inc.
Moleculin Highlights Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting Highlighting Cardiac Safety Data for Annamycin
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Reports First Quarter 2026 Financial Results and Provides Clinical Update on Pivotal MIRACLE Trial
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Announces Imminent MIRACLE Trial Unblinding as Blinded Data Continue to Significantly Outperform Historical Benchmarks
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX
Moleculin Biotech Secures Strategic Additional Patent, Strengthening Global Positioning of Annamycin
globenewswire.com
MBRX
Form 8-K
sec.gov
MBRX